The dose escalation design tested different starting doses (2 mg vs 4 mg) to evaluate tolerability
3 Garvey WT, Batterham RL, Bhatta M, et al
Originally developed for type 2 diabetes, they are transforming the management of this epidemic, which affects over 100 million Indians
Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes
Pills = more convenient, lower cost Shots = higher effectiveness Pills (~1214% weight loss) vs Shots (~20%) The key trend: Patients are increasingly choosing convenience + affordability over maximum efficacy This marks a shift from niche, high-performance treatments mass-access therapies
Andrea Bedrosian, Bariatric Surgeon